



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

To,
The Corporate Relations Department,
BSE Ltd.

November 14, 2023

Sub: Outcome of Board Meeting held on 14.11.2023

We wish to inform you that the Board of Directors of the Company in their Board Meeting held today i.e., 14.11.2023, inter alia, considered and approved the following:

1. Unaudited Standalone and consolidated financial results for the half year ended 30.09.2023.
2. Took note of the Limited Review Report issued by the statutory auditors on the unaudited financial statements for the above said period.
3. Took note and approved the change in designation of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) from Whole Time Director to Non-Executive Director w.e.f 14.11.2023.

Please find enclosed the standalone and consolidated financial results for the period ended 30.09.2023 along with the Limited Review Report issued by the statutory auditors of the Company.

Additional disclosures under SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09.09.2015 w.r.t to change in designation of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) is enclosed as **Annexure A**.

The meeting commenced at 6.00 P.M. and concluded at 7:40 P.M.

This for your information and dissemination to the public.

for VANTA BIOSCIENCE LIMITED
(Scrip Code: 540729 | Scrip ID: VANTABIO)

VENKATA SATHYA MURALI DOKKA
CHIEF FINANCIAL OFFICER



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

Annexure A

Change in Designation of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757)

- Reason for change viz. appointment, resignation, removal, death or otherwise –**
Owing to his pre-occupations and other professional commitments, he has stepped down as Whole Time Director and shall continue as Non-Executive Director of the Company.
- Date of appointment/cessation (as applicable) & term of appointment: -**
Change in designation of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) from Whole Time Director to Non-Executive Director w.e.f 14.11.2023. He was previously appointed as WTD for a period of 5 years w.e.f 01.04.2023.
- Brief profile –** Dr. Vyasmurti holds a doctor of philosophy (pathology) degree from the Agricultural University, Thrissur, Kerala, India. He holds a master of veterinary science (pathology) degree from the Konkan Krishi Vidyapeeth, Dapoli, India. He holds a bachelor of veterinary science and animal husbandry degree from the Konkan Krishi Vidyapeeth, Dapoli, India. A Veterinary Pathologist by profession, Dr. Vyasmurti has more than 12 years of experience as academician and 18 years of experience in the pharmaceutical sector. He has successfully completed 'Laboratory Assessor Training Course' of National Accreditation Board for Testing and Calibration Laboratories (NABL) from Indian Institute of Quality Management, Jaipur.
- Disclosure of relationships between directors (in case of appointment of a director) –** Not Applicable

He has not been debarred from holding office of Director, by virtue of any SEBI Order or any other Authority.



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on unaudited standalone half yearly and year to date financial results of the Company

**To The Board of Directors of
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Vanta Bioscience Limited ("the Company") for the half year ended on 30th September, 2023 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS



K MATHESH REDDY
M. No. 026285 Partner

Place: Hyderabad

Date: 14.11.2023

UDIN: 23026285BGXNH02059



**Independent Auditor's Limited Review Report on unaudited consolidated half yearly
and year to date financial results of the Company**

**To The Board of Directors of
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Vanta Bioscience Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred as "the Group") for the half year ended on 30th September, 2023 ("the statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Vanta Bioscience Limited- Parent Company
 - b. Vanta Clinical Research Limited- Subsidiary Company
 - c. Vayam Research Solutions Limited- Associate Company of Subsidiary
5. Based on our review conducted and procedure performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.





MATHESH & RAMANA
CHARTERED ACCOUNTANTS

6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of 1 subsidiary and 1 associate of subsidiary which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total assets of Rs. 3,863.80 Lakhs as at September 30, 2023, total revenues of Rs. 94.36 Lakhs for the half year ended September 30, 2023, total net profit after tax of Rs. (240.20) Lakhs and cash flows (net outflow) of Rs. (0.99) Lakhs for the period from 1st April, 2023 to 30th September, 2023, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.



For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

K. MATHESH REDDY
M. No. 026285 Partner

Place: Hyderabad

Date: 14.11.2023

UDIN: 23026285BGXNHP4757

VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2023					
(Rupees. In Lacs)					
Sr.No	Particulars	STANDALONE			
		HALF YEAR ENDED			YEAR ENDED
		30.09.2023	30.09.2022	31.03.2023	31.03.2023
		(Un Audited)	(Un Audited)	(Audited)	(Audited)
1	Income				
	Revenue from Operation	523.24	170.50	346.59	517.10
	Other Income	0.00	0.60	61.94	62.53
	Total Revenue	523.24	171.10	408.53	579.63
2	Expenses				
	a) Cost of material Consumed	49.81	19.47	37.37	56.84
	b) Changes In Inventories : Work in progress	0.00	0.00	11.42	11.42
	b) Employee Benefit Expenses	141.79	61.12	217.74	278.86
	c) Financial Cost	130.73	119.75	190.93	310.68
	d) Depreciation and amortization Exp	62.61	62.44	62.60	125.03
	e) other expenses	123.30	57.63	159.90	217.53
	Total Expenses	508.24	320.41	679.96	1000.37
3	Profit/(Loss) from ordinary activities before Exceptional Items (1-2)	15.00	-149.30	-271.43	-420.74
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00
5	Profit/(Loss) from ordinary activities before tax (3+4)	15.00	-149.30	-271.43	-420.74
6	Minority Interest	0.00	0.00	0.00	0.00
7	Net Profit/(Loss) after Minority Interest (5-6)	15.00	-149.30	-271.43	-420.74
8	Tax Expenses				
	a) Current Tax	(3.62)	0.00	0.00	0.00
	b) MAT Credit Availed	0.00	0.00	0.00	0.00
	c) Deferred Tax	1.07	(1.41)	(1.40)	(2.81)
9	Net Profit/(Loss) from ordinary activities after tax (7+8)	12.45	-150.72	-272.83	-423.55
10	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00
11	Total Comprehensive Income/(Loss) Net of Tax (9+10)	12.45	-150.72	-272.83	-423.55
12	Paid up Equity share capital (face value of Rs.10/-)	631.20	631.20	631.20	631.20
13	Reserve excluding Revaluation reserve				
14	Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.20	-2.39	-4.32	-6.71
	b) Diluted (Rs.)	0.20	-2.39	-4.32	-6.71
	Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	0.20	-2.39	-4.32	-6.71
	b) Diluted (Rs.)	0.20	-2.39	-4.32	-6.71

For and on behalf of Board of Directors

Vanta Bioscience Limited

Dopesh Raja Mulakala

Managing Director

DIN:01176660

Place : Hyderabad

Date : 14.11.2023



VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2023					
(Rupees. In Lacs)					
Sr.No	Particulars	CONSOLIDATED			
		HALF YEAR ENDED			YEAR ENDED
		30.09.2023	30.09.2022	31.03.2023	31.03.2023
		(Un Audited)	(Un Audited)	(Audited)	(Audited)
1	Income				
	Revenue from Operation	617.59	282.35	345.24	627.59
	Other Income	2.97	1.09	67.62	68.72
	Total Revenue	620.56	283.44	412.87	696.30
2	Expenses				
	a) Cost of material Consumed	78.29	41.28	42.06	83.34
	b) Changes In Inventories : Work in progress	0.00	0.00	11.42	11.42
	b) Employee Benfit Expenses	169.28	113.07	281.22	394.29
	c) Financial Cost	284.97	248.21	340.38	588.59
	d) Depreciation and amortization Exp	154.48	131.08	135.95	267.03
	e) other expenses	163.57	182.76	195.16	377.92
	Total Expenses	850.59	716.39	1006.20	1722.59
3	Profit/(Loss) from ordinary activities before Exceptional Items (1-2)	-230.03	-432.95	-593.34	-1026.29
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00
5	Profit/(Loss) from ordinary activities before tax (3+4)	-230.03	-432.95	-593.34	-1026.29
6	Minority Interest	-174.12	-186.30	-210.11	-396.41
7	Net Profit/(Loss) after Minority Interest (5-6)	-55.91	-246.65	-383.23	-629.88
8	Tax Expenses				
	a) Current Tax	(3.62)	0.00	0.00	0.00
	b) MAT Credit Availed	0.00	0.00	0.00	0.00
	c) Deferred Tax	5.89	(9.40)	(8.79)	(18.19)
9	Net Profit/(Loss) from ordinary activities after tax (7+8)	-53.64	-256.05	-392.02	-648.07
10	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00
11	Total Comprehensive Income/(Loss) Net of Tax (9+10)	-53.64	-256.05	-392.02	-648.07
12	Paid up Equity share capital (face value of Rs.10/-)	631.20	631.20	631.20	631.20
13	Reserve excluding Revaluation reserve				
14	Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	-0.85	-4.06	-6.21	-10.27
	b) Diluted (Rs.)	-0.85	-4.06	-6.21	-10.27
	Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised)				
	a) Basic (Rs.)	-0.85	-4.06	-6.21	-10.27
	b) Diluted (Rs.)	-0.85	-4.06	-6.21	-10.27

For and on behalf of Board of Directors

Vanta Bioscience Limited

Dopesh Raja Mulakata

Managing Director

DIN:01176660

Place : Hyderabad

Date : 14.11.2023



VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF ASSETS & LIABILITIES AS ON 30th SEPTEMBER 2023					
Sr.No.	Particulars	STANDALONE		CONSOLIDATED	
		30.09.2023	31.03.2023	30.09.2023	31.03.2023
		Un Audited	Audited	Un Audited	Audited
A	Equity and Liabilities				
1	EQUITY				
	a) Equity share capital	631.20	631.20	631.20	631.20
	b) Reserve & Surplus	1355.42	1342.97	1066.64	1120.27
	c) Non Controlling/Minority Interest	0.00	0.00	232.37	141.49
	Sub total Equity	1986.62	1974.17	1930.21	1892.96
	LIABILITIES				
2	Non Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	1790.59	2084.04	4599.00	4706.70
	b) Provisions	0.00	0.00	0.00	0.00
	c) Deferred tax Liabilities	80.10	81.17	90.65	96.55
	d) Other Non Current Liabilities	0.00	0.00	0.00	0.00
	Sub Total -Non Current Liabilities	1870.69	2165.21	4689.65	4803.24
3	Current Liabilities				
	a) Financial Liabilities				
	i) Borrowings	670.07	491.82	1112.34	1009.45
	ii) Trade Payables	151.95	236.02	380.12	421.90
	b) Other Current Liabilities	312.09	296.66	347.91	343.36
	c) Provisions	0.00	0.00	0.00	0.00
	d) Current tax Liabilities(net)	0.00	0.00	0.00	0.00
	Sub Total -Non Current Liabilities	1134.11	1024.50	1840.37	1774.70
	Total Equity and Liabilities	4991.42	5163.88	8460.23	8470.91
B	ASSETS				
1	Non Current Assets				
	a) Property, Plant and Equipment	1277.99	1340.60	3083.87	3322.94
	b) Capital Work in Progress	0.00	0.00	0.00	0.00
	c) Other Intangible assets	2399.53	2399.53	2399.53	2399.53
	d) Other Intangible assets under development	0.00	0.00	1309.28	1060.35
	e) Investment in associates and joint ventures	0.00	0.00	0.00	0.00
	f) Financial Assets	0.00	0.00	0.00	0.00
	i) Investments in Subsidiary	300.00	300.00	0.00	0.00
	ii) Loans	0.00	0.00	0.00	0.00
	iii) Other Financial Assets	0.00	0.00	0.00	0.00
	g) Deferred tax assets (net)	0.00	0.00	0.00	0.00
	h) Other non current assets	0.94	10.65	154.08	163.79
	Sub Total Non-CurrentAssets	3978.46	4050.78	6946.76	6946.62
2	Current Assets				
	a) Inventories	710.85	715.75	710.85	715.75
	b) Financial Assets				
	i) Investments	0.00	0.00	0.00	0.00
	ii) Trade Receivable	121.53	192.33	208.14	195.89
	iii) Bank, Cash and Cash equivalents	11.64	6.65	13.66	9.66
	iv) Loans & Advances	108.55	138.55	511.13	537.99
	iv) Othe Financial Assets	0.00	0.00	0.00	0.00
	c) Current Tax Assets (net)	0.00	0.00	0.00	0.00
	d) Other Current Assets	60.39	59.81	69.69	65.00
	Sub Total Current Assets	1012.96	1113.10	1513.47	1524.29
	Total Assets	4991.42	5163.88	8460.23	8470.91

For and on behalf of Board of Directors

Dopesh Raja Mulakala

Dopesh Raja Mulakala
Managing Director
DIN:01176660



Place : Hyderabad
Date : 14.11.2023

VANTA BIOSCIENCE LIMITED
Cash Flow statement for the period ended 30th SEPTEMBER,2023

(Rupees in Lacs)

Particulars	STANDALONE		CONSOLIDATED	
	For the Half Year ended 30.09.2023	For the Year ended 31.03.2023	For the Half Year ended 30.09.2023	For the Year ended 31.03.2023
A. Cash Flow from Operating Activities				
Profit before exceptional , Extraordinary items and Tax	15.00	(420.74)	(230.03)	(1,026.29)
Adjustment for:				
Depreciation	62.61	125.03	154.49	267.03
Finance Charges	130.73	310.68	284.97	588.59
Profit on Sale of Fixed Assets	-	-	-	-
Sub total	193.34	435.71	439.46	855.62
Operating profit Before Working Capital Changes	208.34	14.98	209.43	(170.67)
Adjustment for:				
(Increase) /Decrease in Inventories	4.91	7.80	4.91	7.80
(Increase) /Decrease in Trade receivables	70.80	-120.03	(12.26)	(82.48)
Increase /(Decrease) in Current Liabilities	-68.64	46.81	(37.23)	128.50
(Increase) /Decrease Loans & Advances	39.12	114.91	26.85	(19.62)
(Increase) /Decrease Current Assets	-	-	5.02	73.71
(Increase) /Decrease in Current Investment	-	0.00	-	-
Sub total	46.19	49.49	(12.71)	107.91
Cash Generated from operations	254.53	64.47	196.72	(62.76)
Net Cash Flow from Operating Activities	254.53	64.47	196.72	(62.76)
B: Cash Flow from Investing Activities				
Purchase of Fixed Assets	-	(253.02)	(164.33)	(2,868.90)
Capital Work In progress	-	-	-	2,278.03
Capital Work in progress-R&D	-	-	-	-
proceeds from sale of Fixed Assets	-	-	-	-
Investment in Subsidiaries	-	-	-	-
Purchase of other Non current Investments	-	-	-	-
Net Cash Flow from Investing Activities	-	(253.02)	(164.33)	(590.87)
C: Cash Flow from Financing Activities				
Increase /(Decrease) in Unsecured Loan	-	-	229.76	384.97
Increase /(Decrease) in Working capital	178.24	-20.76	102.89	51.34
Increase /(Decrease) in Term Loan	-293.43	519.73	(337.46)	793.15
Increase /(Decrease) in Long Term Borrowings	-	-	-	-
Increase /(Decrease) in Short Term Borrowings	-	-	-	-
Increase /(Decrease) in share capital	-	-	265.00	-
Increase /(Decrease) in share Premium	-	-	-	-
Finance Charges	-130.73	(310.68)	(284.97)	(588.59)
Net Cash Flow from Financing Activities	(245.92)	188.29	(24.78)	640.87
Actual Payment of Income Tax	-3.62	0	(3.62)	-
D: Net Increase/Decrease in Cash and cash Equivalents	4.99	(0.26)	3.99	(12.76)
Opening of Cash & Cash Equivalents	6.65	6.91	9.66	22.42
Closing Balance of Cash & Cash Equivalents	11.64	6.65	13.66	9.66

See accompanying notes to the financial statements
As per our report of even date annexed.

Place : Hyderabad
Date : 14.11.2023

For and on behalf of Board of Directors

Vanta Bioscience Limited

Dopesh Raja Mulakala
Managing Director
DIN:01176660



Notes to Standalone and consolidated financial statements:

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th November, 2023.
2. The Statutory Auditors have carried out limited review of the Un Audited Results of the company for the half year ended 30.09.2023.
3. The statement are prepared in accordance with the requirements of accounting standards (AS) specified under section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules 2014.
4. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND AS. Hence it has not adopted IND AS for preparation of Financial Statements.
5. Statement of Assets and Liabilities as on 30th September 2023 is enclosed herewith.
6. Statement of Cash flow for the period ended 30th September 2023 is enclosed herewith.
7. The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.
8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
9. The said results are uploaded on the website of the Company www.vantabio.com and on BSE Ltd.

